195 related articles for article (PubMed ID: 38280454)
1. Phenotyping of Severe Asthma in the Era of Broad-Acting Anti-Asthma Biologics.
Bourdin A; Brusselle G; Couillard S; Fajt ML; Heaney LG; Israel E; McDowell PJ; Menzies-Gow A; Martin N; Mitchell PD; Petousi N; Quirce S; Schleich F; Pavord ID
J Allergy Clin Immunol Pract; 2024 Apr; 12(4):809-823. PubMed ID: 38280454
[TBL] [Abstract][Full Text] [Related]
2. Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma.
Porsbjerg CM; Townend J; Bergeron C; Christoff GC; Katsoulotos GP; Larenas-Linnemann D; Tran TN; Al-Lehebi R; Bosnic-Anticevich SZ; Busby J; Hew M; Kostikas K; Papadopoulos NG; Pfeffer PE; Popov TA; Rhee CK; Sadatsafavi M; Tsai MJ; Ulrik CS; Al-Ahmad M; Altraja A; Beastall A; Bulathsinhala L; Carter V; Cosio BG; Fletton K; Hansen S; Heaney LG; Hubbard RB; Kuna P; Murray RB; Nagano T; Pini L; Cano Rosales DJ; Schleich F; Wechsler ME; Amaral R; Bourdin A; Brusselle GG; Chen W; Chung LP; Denton E; Fonseca JA; Hoyte F; Jackson DJ; Katial R; Kirenga BJ; Koh MS; Ławkiedraj A; Lehtimäki L; Liew MF; Mahboub B; Martin N; Menzies-Gow AN; Pang PH; Papaioannou AI; Patel PH; Perez-De-Llano L; Peters MJ; Ricciardi L; Rodríguez-Cáceres B; Solarte I; Tay TR; Torres-Duque CA; Wang E; Zappa M; Abisheganaden J; Assing KD; Costello RW; Gibson PG; Heffler E; Máspero J; Nicola S; Perng Steve DW; Puggioni F; Salvi S; Sheu CC; Sirena C; Taillé C; Tan TL; Bjermer L; Canonica GW; Iwanaga T; Jiménez-Maldonado L; Taube C; Brussino L; Price DB
Front Immunol; 2024; 15():1361891. PubMed ID: 38711495
[TBL] [Abstract][Full Text] [Related]
3. Definition, Phenotyping of Severe Asthma, Including Cluster Analysis.
Casanova S; Ahmed E; Bourdin A
Adv Exp Med Biol; 2023; 1426():239-252. PubMed ID: 37464124
[TBL] [Abstract][Full Text] [Related]
4. Biologics in the treatment of asthma in children and adolescents.
Bacharier LB; Jackson DJ
J Allergy Clin Immunol; 2023 Mar; 151(3):581-589. PubMed ID: 36702649
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and Management of Severe Asthma.
Chung KF
Semin Respir Crit Care Med; 2018 Feb; 39(1):91-99. PubMed ID: 29427989
[TBL] [Abstract][Full Text] [Related]
6. Biologics for severe asthma-Which, when and why?
Shah PA; Brightling C
Respirology; 2023 Aug; 28(8):709-721. PubMed ID: 37222237
[TBL] [Abstract][Full Text] [Related]
7. Emerging care management strategies for severe asthma: integrating biologic therapy.
Spjut R
Am J Manag Care; 2022 Sep; 28(11 Suppl):S203-S209. PubMed ID: 36648385
[TBL] [Abstract][Full Text] [Related]
8. Severe asthma exacerbations in the United States:: Incidence, characteristics, predictors, and effects of biologic treatments.
Trevor J; Lugogo N; Carr W; Moore WC; Soong W; Panettieri RA; Desai P; Trudo F; Ambrose CS
Ann Allergy Asthma Immunol; 2021 Nov; 127(5):579-587.e1. PubMed ID: 34273485
[TBL] [Abstract][Full Text] [Related]
9. A Review of the Utility and Cost Effectiveness of Monitoring Fractional Exhaled Nitric Oxide (FeNO) in Asthma Management.
Arnold RJ; Massanari M; Lee TA; Brooks E
Manag Care; 2018 Jul; 27(7):34-41. PubMed ID: 29989900
[TBL] [Abstract][Full Text] [Related]
10. Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma.
Gallagher A; Edwards M; Nair P; Drew S; Vyas A; Sharma R; Marsden PA; Wang R; Evans DJ
Cochrane Database Syst Rev; 2021 Oct; 10(10):CD012929. PubMed ID: 34664263
[TBL] [Abstract][Full Text] [Related]
11. Characteristics, phenotypes, mechanisms and management of severe asthma.
Chung KF; Dixey P; Abubakar-Waziri H; Bhavsar P; Patel PH; Guo S; Ji Y
Chin Med J (Engl); 2022 May; 135(10):1141-1155. PubMed ID: 35633594
[TBL] [Abstract][Full Text] [Related]
12. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
[TBL] [Abstract][Full Text] [Related]
13. When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report.
Sabbe M; Schleich F; Janssens P; Louis R
J Med Case Rep; 2024 Jan; 18(1):63. PubMed ID: 38291489
[TBL] [Abstract][Full Text] [Related]
14. Clinical and economic burden of severe asthma among US patients treated with biologic therapies.
Reibman J; Tan L; Ambrose C; Chung Y; Desai P; Llanos JP; Moynihan M; Tkacz J
Ann Allergy Asthma Immunol; 2021 Sep; 127(3):318-325.e2. PubMed ID: 33775904
[TBL] [Abstract][Full Text] [Related]
15. Controversies in Allergy: Choosing a Biologic for Patients with Severe Asthma.
Pavord ID; Hanania NA; Corren J
J Allergy Clin Immunol Pract; 2022 Feb; 10(2):410-419. PubMed ID: 34958982
[TBL] [Abstract][Full Text] [Related]
16. The management of severe asthma in 2020.
Côté A; Godbout K; Boulet LP
Biochem Pharmacol; 2020 Sep; 179():114112. PubMed ID: 32598948
[TBL] [Abstract][Full Text] [Related]
17. An Emerging Role for Exhaled Nitric Oxide in Guiding Biological Treatment in Severe Asthma.
Rolla G; Heffler E; Pizzimenti S; Michils A; Malinovschi A
Curr Med Chem; 2020; 27(42):7159-7167. PubMed ID: 32660394
[TBL] [Abstract][Full Text] [Related]
18. Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions.
Oppenheimer J; Hoyte FCL; Phipatanakul W; Silver J; Howarth P; Lugogo NL
Ann Allergy Asthma Immunol; 2022 Aug; 129(2):169-180. PubMed ID: 35272048
[TBL] [Abstract][Full Text] [Related]
19. Pragmatic Clinical Perspective on Biologics for Severe Refractory Type 2 Asthma.
Chan R; RuiWen Kuo C; Lipworth B
J Allergy Clin Immunol Pract; 2020; 8(10):3363-3370. PubMed ID: 32673880
[TBL] [Abstract][Full Text] [Related]
20. Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion.
Buhl R; Bel E; Bourdin A; Dávila I; Douglass JA; FitzGerald JM; Jackson DJ; Lugogo NL; Matucci A; Pavord ID; Wechsler ME; Kraft M
J Allergy Clin Immunol Pract; 2022 Feb; 10(2):422-432. PubMed ID: 34763123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
